Are you among the estimated 100,000 women in the UK who were fitted with an Essure implant? If so, you may be eligible to join our group action and claim compensation.
Essure, manufactured by Bayer HealthCare, is the only non-surgical permanent form of birth control for women in the UK. Made of a metal coil and plastic PET fibers, the device is known to slice through the uterus and fallopian tubes, migrate into the pelvis or abdomen, and cause allergic and autoimmune reaction to the materials, maiming thousands of women like you.
Left in crippling pain and facing limited treatment options, many women have had to endure multiple surgeries to remove Essure, a complex procedure that often calls for a total hysterectomy in order to remove the tiny metal fragments that break off from the device.
We believe you and know your pain is real.
For far too long women’s pain has been ignored and dismissed by the medical profession whilst women in the UK continued to receive Essure implants. Stop suffering in silence.
Essure is a permanent sterilization process which is different than a coil, hormonal intrauterine device (IUD) or Filshie clip. The Essure device has springs which are placed into both fallopian tubes to create a barrier, or scarring. This is caused by pet fibres within the Essure coils or springs.
Unlike other methods, Essure is normally fitted whilst a patient is awake. If someone is unsure about which method was used, they can contact their GP or the hospital that carried out the process.
Conceptus, who developed Essure and was later acquired by Bayer, failed to properly research, design and test Essure and then sold this unreasonably dangerous device without adequately warning women and the medical community about its risks. In the UK and around the world, thousands of women have been harmed as a result.
Pogust Goodhead is committed to seeking justice for these women.
If you have experienced any of the following side effects as a result of your Essure implant, you may be eligible for compensation:
We have assembled a powerful team of the UK’s leading solicitors and barristers reinforced with the financial resources and tested expertise of American class action lawyers to ensure that your case is aggressively litigated against Bayer.
We are passionate about winning this group action! Pogust Goohead’s American partners currently represent over 1,500 women in the United States who have received Essure implants and have already won over $1 billion of compensation for consumers in similar cases.
We operate on a no-win, no-fee basis, and unlike other law firms, we cap our fees and aim to secure the maximum compensation owed to you for your pain and suffering and financial losses. We do everything for you and make your claim simple.
Join together with thousands of other determined women in the UK and hold Essure’s manufacturer to account!
Pogust Goohead understands that no amount of money can repair bodies, broken families or the loss of loved ones that has resulted from Essure complications. In many cases, compensation can pay for the extensive treatments and multiple repair surgeries needed to survive and improve your quality of life. For many of our clients, compensation is more than money: it’s public vindication that the medical community should have listened to you and taken your concerns seriously. It’s a way to hold Essure’s manufacturer to account and save other women from being harmed in the future.
We have litigated thousands of similar cases in the USA and have secured compensation for our clients for the following:
We are committed to achieving the same levels of maximum compensation for your claim.
Currently in the US, Bayer is facing over 16,000 lawsuits filed by women who experienced injuries and complications from Essure implants. Despite 30,000 patients reporting problems about Essure to the FDA, the pharmaceutical company is staunchly defending itself against allegations that it intentionally misled women and actively concealed negative reports about the device from the FDA.
While Bayer voluntarily withdrew sales of Essure from the UK market in September 2017, neither it nor the Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of the device. Sadly, this means more women can receive an Essure implant from already sold stock.
Shockingly, Essure was approved in 2002 with little testing, shepherded in a fast-track FDA approval process by a company executive who also served on the FDA panel responsible for reviewing the safety and efficacy of contraceptive devices. Required to conduct a 5-year follow-up study after Essure’s approval, Bayer was 8 years late in publishing its finding and only 70% of participants had been tracked.
In another example of profit over patient safety, Essure’s labelling was changed so that doctors would no longer be required to test women for nickel allergies and could still offer Essure to women allergic to nickel. Approximately 55% of the Essure is made of nickel and 20% of women have nickel allergies.
Even when Essure’s labelling was modified again in 2016 to include a Black Box Warning (the most serious warning label that can be placed on a medical device), it made little difference in forewarning women of the risks of Essure since many patients are not provided with Essure’s packaging. Moreover, the Patient Decision Checklist, crafted to ensure informed consent, was never mandated until after Essure was pulled from the UK market.
The depth and breadth of this scandal is truly appalling:
NOVEMBER 4, 2002
FDA fast-tracks the application, granting Essure developer, Conceptus approval to market the device in the US.
Essure first marketed in the UK.
Bayer acquires Conceptus for $1.1 billion.
First lawsuit filed against Bayer with allegations that the pharmaceutical company intentionally misled women implanted with Essure and actively concealed negative reports about the device from the FDA.
FDA holds first public hearing on Essure after receiving 5,000 adverse event reports on the device.
FDA orders Bayer to a post-market surveillance study to investigate the safety and efficacy of Essure.
END OF 2016
FDA reports sales of Essure plummeted by 70% after implementation of Black Box Warning.
Bayer adopts the FDA’s recommendations and adds the boxed warning and patient checklist to Essure labelling, however, not all doctors opt to ask patients to sign the Patient Decision Checklist since it is not mandatory.
MAY 29, 2017
Bayer announces withdrawal of Essure from the Netherlands market with the discontinuation for sale and distribution effective July 1, 2017.
FEBRUARY 20, 2017
Brazil bans the sale and distribution of Essure and issues a recall of all devices.
JUNE 16, 2017
Bayer announces withdrawal of Essure from the Canada market over the course of following few months.
MAY 31, 2017
Bayer announces withdrawal of Essure from the Finland market with the discontinuation for sale and distribution effective June 25, 2017.
SEPTEMBER 1, 2017
Bayer voluntarily ends non-US sales of Essure.
European Union suspends sales of Essure in the 28-nation bloc for three months from August in response to regulatory concern. The EU’s suspension means that while the sale of Essure is banned, already-sold implants in the supply chain could still be administered by doctors. UK hospitals urged to avoid using the device.
FDA, in a partial reversal of its October 2016 decision, makes Patient Decision Checklist mandatory for all doctors.
END OF 2017
FDA receives nearly 26,773 complaints about Essure from US patients from 2002 through 2017. Bayer has also independently received over 30,000 complaints about the device.
Essure lawsuits continue to be filed globally with over 16,000 in the US alone. Pogust Goohead (was PGMBM) brings its expertise to the UK to help women globally get justice and the compensation they deserve.
JULY 20, 2018
Bayer announces it will no longer distribute or sell Essure in the US beyond December 31, 2018, citing it as a “business decision” spurred by a 40% drop in US sales in recent years. However, doctors will still be able to perform Essure procedures in the US throughout 2019, until they are asked to return unused devices at the end of the year.
A. Sadly, unless you have had removal surgery, or been recommended for removal surgery by your doctor, you won’t meet the eligibility criteria to make a claim.
A. There have not yet been any major verdicts or settlements in Essure lawsuits against the manufacturer, Bayer HealthCare. However, if you have experienced complications, you may be able to make a claim. The level of compensation you may receive can vary based on a number of factors, including:
There are no upfront costs when signing up with Pogust Goodhead.
We accept* instructions on a No-Win, No-Fee basis. This means that you will not have to pay any of our costs unless and until your case is successful (as long as you comply with your obligations) and we obtain compensation for you.
Under the terms of this agreement, you will only be liable to pay our fees and expenses, as well as those of barristers, funders and insurers (if applicable), if the case is successful. The exact amount you will pay will depend upon how long the case takes, how much time we need to spend on it, and the level of compensation obtained.
Unlike some other firms, we cap our deduction from your damages at a maximum of 35%, inclusive of VAT, of the compensation you receive.
Additionally, your case is protected by Qualified One-Way Costs Shifting (“QOCS”). This means that if your case is unsuccessful the defendants will not be able to recover their costs from you. Please note that QOCS can be disapplied if the claim if found to be fundamentally dishonest, or is struck out for having no reasonable grounds for being brought. In those circumstances the defendants would be entitled to recover their costs from you.
*Eligibility criteria apply
A. No. We will arrange all necessary insurance and funding on your behalf.
Pogust Goodhead – an internationally recognised law firm
Pogust Goodhead (a trading name of PGMBM Law Limited) – SRA License Number 512898
Pogust Goodhead is authorised and regulated by the Solicitors Regulation Authority and
complies with the Solicitors Code of Conduct, a copy of which can be located here.